Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2004, Vol. 15 ›› Issue (2): 115

• RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICIN • Previous Articles     Next Articles

Radioiodide uptake in melanoma cells after transfer of human NaI symporter gene

CHEN Li-Bo,1 ZHU Rui-Sen,1 LU Han-Kui,1 YU Yong-Li,1 LUO Quan-Yong,1 HUANG Fang,2 FEI Jian,2 GUO Li-He2   

  1. 1Department of Nuclear Medicine, Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai 200233;
    2Institute of Biochemistry and Cell Biology, the Chinese Academy of Sciences, Shanghai 200031
PDF ShareIt Export Citation
CHEN Li-Bo, ZHU Rui-Sen, LU Han-Kui, YU Yong-Li, LUO Quan-Yong, HUANG Fang, FEI Jian, GUO Li-He. Radioiodide uptake in melanoma cells after transfer of human NaI symporter gene.Nuclear Science and Techniques, 2004, 15(2): 115

Abstract: To obtain human sodium/iodide symporter gene cDNA for studying its potential ability as a radioiodide treatment for melanoma, the hNIS gene cDNA was amplified with total RNA from human thyroid tissue by RT-PCR. The hNIS cDNA was inserted into cloning vector pUCm-T and subcloned into eukaryotic expression vector pc-DNA3. The pc-DNA3-hNIS and pc-DNA3 were transduced into melanoma cells (B16) by electroporation, and two cell lines termed B16-A and B16-B respectively were established. The uptake and efflux of iodide was examined in vitro. The three cell lines (B16-A, B16-B, B16) were injected subcutaneously into the right flank of C57 mice. Biodistribution study and tumor imaging were performed when the tumor reached approximately 10mm in diameter. The cloned hNIS cDNA sequence was identical with the published sequence. Two novel cell lines named 16-A containing pc-DNA3-hNIS and B16-B containing pc-DNA3 only were established. The resultant cell line B16-A accumulated 17 and 19 times more radioiodide in vitro than B16 and B16-B respectively. The iodide uptake reached the half-maximal level within 10 min, and reached a plateau at 30 min. The efflux of iodide was also rapid (T1/2eff=10min). The imaging shows in vivo uptake in expected sites including the salivary glands, thyroid, stomach, and hNIS-transduced tumor, whereas the nontransduced tumor was not visualized. The %ID/g of B16-A tumors at 1, 2, 4, 12, and 24h after injection of 125I were 12.22±0.71, 10.91±0.72, 8.73±0.99, 1.24±0.29, and 0.19±0.03, respectively, which were significantly higher percentages than those for controlling tumors, p<0.01. However, biologic T1/2 was about 6 h. Our preliminary data indicate that the transduction of the hNIS gene per se is sufficient to induce iodide transport in melanoma cells both in vitro and in vivo, but T1/2eff is short.

Key words: Radioiodide, Human NaI symporter, Gene therapy, Melanoma